Stockreport

Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5%

AKORN  (AKRX) 
Last akorn earnings: 10/31 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.akorn.com
PDF LAKE FOREST, Ill., April 18, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received [Read more]